Recent Progress in Gene Therapy for Familial Hypercholesterolemia Treatment

Overview

Journal iScience

Publisher Cell Press

Date 2024 Sep 12

PMID 39262805

Authors

Yaxin Luo

Yaofeng Hou

Wenwen Zhao

Bei Yang

Affiliations

Soon will be listed here.

Abstract

Familial hypercholesterolemia (FH) is a genetic disorder that affects 1 in 300 people, leading to high cholesterol levels and significantly increased cardiovascular risk. The limitations of existing FH treatments underscore the need for innovative therapeutics, and gene therapy offers a promising alternative to address FH more effectively. In this review, we survey approved gene therapy drugs first and then delve into the landscape of gene addition, gene inactivation, and gene editing therapies for hypercholesterolemia, highlighting both approved interventions and those in various stages of development. We also discussed recent advancements in gene editing tools that are essential for their application in gene therapy. Safety considerations inherent to gene therapy are also discussed, emphasizing the importance of mitigating potential risks associated with such treatments. Overall, this review highlights the progress and prospects of gene therapies for FH treatments, underscoring their potential to revolutionize the management of this prevalent and challenging condition.

References

Dewey F, Gusarova V, Dunbar R, ODushlaine C, Schurmann C, Gottesman O . Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3):211-221. PMC: 5800308. DOI: 10.1056/NEJMoa1612790. View

Yang L, Chen J . A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing. Trends Biochem Sci. 2020; 45(10):874-888. DOI: 10.1016/j.tibs.2020.06.003. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Rezaie J, Feghhi M, Etemadi T . A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022; 20(1):145. PMC: 9483361. DOI: 10.1186/s12964-022-00959-4. View

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

Zhu Y, Lin X, Zhou X, Prochownik E, Wang F, Li Y . Posttranslational control of lipogenesis in the tumor microenvironment. J Hematol Oncol. 2022; 15(1):120. PMC: 9422141. DOI: 10.1186/s13045-022-01340-1. View

Watts G, Gidding S, Mata P, Pang J, Sullivan D, Yamashita S . Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020; 17(6):360-377. DOI: 10.1038/s41569-019-0325-8. View

Xu Y, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A . Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 2017; 268:196-206. PMC: 5750127. DOI: 10.1016/j.atherosclerosis.2017.08.031. View

Tardif J, Karwatowska-Prokopczuk E, Amour E, Ballantyne C, Shapiro M, Moriarty P . Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022; 43(14):1401-1412. PMC: 8986458. DOI: 10.1093/eurheartj/ehab820. View

10.

Ward N, Watts G, Eckel R . Statin Toxicity. Circ Res. 2019; 124(2):328-350. DOI: 10.1161/CIRCRESAHA.118.312782. View

11.

Watts G, Gidding S, Hegele R, Raal F, Sturm A, Jones L . International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023; 20(12):845-869. DOI: 10.1038/s41569-023-00892-0. View

12.

Brandts J, Ray K . Familial Hypercholesterolemia: JACC Focus Seminar 4/4. J Am Coll Cardiol. 2021; 78(18):1831-1843. DOI: 10.1016/j.jacc.2021.09.004. View

13.

Rao A, Lindholm D, Rivas M, Knowles J, Montgomery S, Ingelsson E . Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic Stroke. Circ Genom Precis Med. 2018; 11(7):e002162. PMC: 6050027. DOI: 10.1161/CIRCGEN.118.002162. View

14.

Guide S, Gonzalez M, Bagci I, Agostini B, Chen H, Feeney G . Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022; 387(24):2211-2219. DOI: 10.1056/NEJMoa2206663. View

15.

Utermann G, Weber W . Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett. 1983; 154(2):357-61. DOI: 10.1016/0014-5793(83)80182-3. View

16.

Sarkar M, Liao J, KABAT E, Tanabe T, ASHWELL G . The binding site of rabbit hepatic lectin. J Biol Chem. 1979; 254(9):3170-4. View

17.

Romeo S, Yin W, Kozlitina J, Pennacchio L, Boerwinkle E, Hobbs H . Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2008; 119(1):70-9. PMC: 2613476. DOI: 10.1172/JCI37118. View

18.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

19.

Ramkumar S, Raghunath A, Raghunath S . Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016; 32(6):631-639. PMC: 5126440. DOI: 10.6515/acs20160611a. View

20.

Horie T, Ono K . VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients. Eur Heart J Cardiovasc Pharmacother. 2023; 10(2):89-90. DOI: 10.1093/ehjcvp/pvad103. View